Rhythm Express: The Medtech Firm Tackling Two Silent Health Crises at Once

MINNEAPOLIS, MN – August 11, 2026 – In the world of business accolades, few are as clear a barometer of sustained success as the Inc. 5000. Landing on the list once is an achievement; doing so for four consecutive years signals a company that has mastered the art of rapid, strategic growth. Minneapolis-based VivaQuant, operating under its better-known brand Rhythm Express, has just crossed that very threshold. But this story isn't just about impressive revenue charts. It’s about how that growth is being fueled by a targeted strategy to solve one of modern healthcare’s most complex diagnostic challenges: the dangerous and often-hidden link between cardiac arrhythmias and sleep disorders.

The company’s fourth Inc. 5000 recognition coincides with the strategic launch of its recently FDA 510(k)-cleared RX-1 Sleep solution, a device that embodies the convergence of medtech, data, and patient-centric design. It’s a move that positions Rhythm Express not just as a fast-growing company, but as a potential market-shaper at the intersection of cardiology and sleep medicine.

A Pattern of Disruptive Growth

To appear on the Inc. 5000 list for four straight years is to demonstrate a rare consistency in a volatile market. The ranking, based on a three-year revenue growth percentage, is a testament to a company’s ability to innovate, scale, and capture market share. For Rhythm Express, this sustained momentum reflects a deep understanding of the evolving needs of the digital health landscape.

“We are honored to be recognized by Inc. Magazine for the fourth year in a row. This recognition reflects the dedication of our team and our commitment to delivering innovative solutions to improve patient care,” said Brian Brockway, CEO of VivaQuant, in a recent statement. His focus, however, quickly pivots from the award to the mission it enables. “As we expand our portfolio with our recently FDA 510(k)-cleared RX-1 Sleep™ solution, we believe we are uniquely positioned to transform how physicians diagnose both arrhythmias and sleep apnea.”

This isn’t just corporate optimism. The company’s track record, having supported physicians in diagnosing heart rhythms for over 650,000 patients, provides a solid foundation. Their core RX-1 mini device has already earned praise from clinicians for its user-friendly design—a small, water-resistant, wireless monitor that boosts patient compliance. One physician noted that the device is "universally praised by patients" for its simplicity and lack of cumbersome wires, calling it "the current cutting edge heart monitoring technology." This existing goodwill is a crucial asset as the company ventures into a more complex diagnostic field.

The Diagnostic Dilemma: Tying Sleep and Heart Health Together

To understand the significance of RX-1 Sleep, one must first appreciate the intertwined nature of the conditions it targets. Cardiac arrhythmias, like atrial fibrillation (AFib), and sleep-related breathing disorders, primarily obstructive sleep apnea (OSA), are two of healthcare’s most pervasive and underdiagnosed problems. Individually, they pose significant health risks. Together, they create a dangerous feedback loop.

According to the American Medical Association, an estimated 30 million adults in the U.S. have OSA, yet the vast majority remain undiagnosed. This is the “silent” part of the crisis. Sufferers experience repeated interruptions in breathing during sleep, leading to drops in blood oxygen levels and stress on the cardiovascular system. Untreated, OSA is a major risk factor for hypertension, heart attack, stroke, and AFib.

Simultaneously, AFib—the most common type of cardiac arrhythmia—is a leading cause of stroke and can be notoriously difficult to detect, as it is often intermittent. The challenge for clinicians has been that these two conditions often require separate diagnostic pathways, involving different specialists, multiple appointments, and cumbersome equipment. A patient might undergo a Holter monitor test for their heart, and then a separate, often inconvenient, overnight study in a sleep lab for apnea. This fragmented approach creates delays, increases costs, and places a significant burden on the patient.

Medical research has firmly established a strong comorbidity between OSA and cardiac arrhythmias. Effectively, the physiological stress from sleep apnea can trigger or worsen heart rhythm problems, and treating the sleep disorder can, in turn, improve cardiac outcomes. This clinical reality has created a clear and urgent need for a unified diagnostic tool.

Introducing RX-1 Sleep: A Unified Approach to Home Diagnostics

This is the precise gap Rhythm Express aims to fill with RX-1 Sleep. The solution elegantly combines the company’s proven RX-1 mini cardiac monitor with a wrist-worn pulse oximeter. This integrated system allows for the concurrent gathering of high-clarity ECG data and blood oxygen saturation levels in a single, simple, at-home test.

Marina Brockway, the company's founder and CTO, explains the strategic advantage: “RX-1 Sleep wirelessly combines our compact RX-1 mini wearable with a small wrist-worn pulse oximeter to concurrently assess severity of sleep related breathing disorders and cardiac arrhythmias in one simple test, providing streamlined and simplified workflows for both patients and clinics.”

The impact of this seemingly simple integration is profound. For patients, it replaces two separate, potentially cumbersome tests with one comfortable, multi-day study performed in their own home. For physicians, it delivers a correlated, holistic dataset, providing a much clearer picture of a patient's cardiopulmonary health during sleep. This can lead to faster, more accurate diagnoses and more effective, personalized treatment plans.

By leveraging the patient-friendly design of the RX-1 mini—which is already known for being shower-proof and wire-free—Rhythm Express is lowering the barrier to compliance, a critical factor in the accuracy of any long-term monitoring test. As Brockway notes, this approach “gives providers actionable clinical insights while reducing obstacles and delays for patients.”

Navigating a Crowded Market with Strategic Innovation

The remote patient monitoring market is not without its titans. Companies like iRhythm, Philips, and Boston Scientific command significant market share. However, Rhythm Express is carving out its niche not by competing on scale alone, but by focusing on strategic innovation that addresses unmet clinical needs. While many competitors offer excellent solutions for either cardiac monitoring or home sleep testing, few have successfully integrated them into a single, seamless platform.

This integrated diagnostic approach places Rhythm Express at the forefront of several key healthcare trends. The shift to remote patient monitoring (RPM) and home-based diagnostics, a trend massively accelerated by the recent pandemic, is now an established pillar of modern healthcare delivery. Patients and providers alike are demanding solutions that are convenient, efficient, and cost-effective. The RX-1 Sleep device is a textbook example of a product built for this new paradigm.

By focusing on the well-documented comorbidity of sleep apnea and arrhythmias, Rhythm Express is executing a savvy business strategy. It is not just selling a device; it is selling a more efficient clinical pathway. This creates value not only for the patient but for the entire healthcare ecosystem, from primary care physicians to cardiologists and sleep specialists, potentially reducing the number of referrals and redundant tests. As the healthcare industry continues its inexorable shift towards value-based care and preventative medicine, companies that can provide holistic, actionable data will be the ones that thrive. Rhythm Express, with its consistent growth and its latest innovation, appears poised to be one of them.